Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
$14.90
-1.5%
$16.14
$13.46
$31.04
$449.78M0.88518,632 shs872,037 shs
Charming Medical Ltd stock logo
MCTA
Charming Medical
$29.36
+6.8%
$29.36
$4.30
$31.70
$497.21MN/AN/A4.25 million shs
Personalis, Inc. stock logo
PSNL
Personalis
$5.56
-5.8%
$7.02
$3.84
$11.50
$617.60M1.961.96 million shs2.21 million shs
Quipt Home Medical Corp. stock logo
QIPT
Quipt Home Medical
$3.65
$3.62
$1.35
$3.65
$162.30M0.54676,348 shsN/A
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
+5.45%-2.61%-11.41%-41.64%-23.82%
Charming Medical Ltd stock logo
MCTA
Charming Medical
0.00%0.00%0.00%0.00%+2,935,999,900.00%
Personalis, Inc. stock logo
PSNL
Personalis
-3.81%+1.09%-15.50%-33.09%+30.52%
Quipt Home Medical Corp. stock logo
QIPT
Quipt Home Medical
0.00%0.00%0.00%+2.53%+69.77%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
$14.90
-1.5%
$16.14
$13.46
$31.04
$449.78M0.88518,632 shs872,037 shs
Charming Medical Ltd stock logo
MCTA
Charming Medical
$29.36
+6.8%
$29.36
$4.30
$31.70
$497.21MN/AN/A4.25 million shs
Personalis, Inc. stock logo
PSNL
Personalis
$5.56
-5.8%
$7.02
$3.84
$11.50
$617.60M1.961.96 million shs2.21 million shs
Quipt Home Medical Corp. stock logo
QIPT
Quipt Home Medical
$3.65
$3.62
$1.35
$3.65
$162.30M0.54676,348 shsN/A
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
+5.45%-2.61%-11.41%-41.64%-23.82%
Charming Medical Ltd stock logo
MCTA
Charming Medical
0.00%0.00%0.00%0.00%+2,935,999,900.00%
Personalis, Inc. stock logo
PSNL
Personalis
-3.81%+1.09%-15.50%-33.09%+30.52%
Quipt Home Medical Corp. stock logo
QIPT
Quipt Home Medical
0.00%0.00%0.00%+2.53%+69.77%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
2.20
Hold$27.0081.21% Upside
Charming Medical Ltd stock logo
MCTA
Charming Medical
1.00
SellN/AN/A
Personalis, Inc. stock logo
PSNL
Personalis
2.57
Moderate Buy$11.50106.83% Upside
Quipt Home Medical Corp. stock logo
QIPT
Quipt Home Medical
1.75
Reduce$3.834.79% Upside

Current Analyst Ratings Breakdown

Latest QIPT, PSNL, MCTA, and FLGT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/5/2026
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
Reiterated RatingNeutral$30.00 ➝ $15.00
4/21/2026
Personalis, Inc. stock logo
PSNL
Personalis
Reiterated RatingSell (D-)
3/5/2026
Personalis, Inc. stock logo
PSNL
Personalis
Lower Price TargetEqual Weight$11.00 ➝ $10.00
2/27/2026
Personalis, Inc. stock logo
PSNL
Personalis
Boost Price TargetBuy$10.00 ➝ $12.00
2/11/2026
Personalis, Inc. stock logo
PSNL
Personalis
Boost Price TargetBuy$12.00 ➝ $13.00
2/9/2026
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
DowngradeStrong-BuyHold
(Data available from 5/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
$322.67M1.37N/AN/A$35.10 per share0.42
Charming Medical Ltd stock logo
MCTA
Charming Medical
N/AN/AN/AN/AN/AN/A
Personalis, Inc. stock logo
PSNL
Personalis
$69.65M8.36N/AN/A$2.94 per share1.89
Quipt Home Medical Corp. stock logo
QIPT
Quipt Home Medical
$264.97M0.61$0.95 per share3.85$2.58 per share1.41
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
-$60.51M-$2.39N/AN/AN/A-23.04%-3.24%-2.97%N/A
Charming Medical Ltd stock logo
MCTA
Charming Medical
N/AN/AN/AN/AN/AN/AN/AN/AN/A
Personalis, Inc. stock logo
PSNL
Personalis
-$81.27M-$0.91N/AN/AN/A-116.69%-39.13%-29.31%5/7/2026 (Confirmed)
Quipt Home Medical Corp. stock logo
QIPT
Quipt Home Medical
-$10.70M-$0.24N/AN/AN/A-4.05%-9.94%-4.10%5/11/2026 (Estimated)

Latest QIPT, PSNL, MCTA, and FLGT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2026Q1 2026
Personalis, Inc. stock logo
PSNL
Personalis
-$0.23N/AN/AN/A$14.48 millionN/A
2/27/2026Q4 2025
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
$0.02$0.16+$0.14-$0.76$85.38 million$83.34 million
2/26/2026Q4 2025
Personalis, Inc. stock logo
PSNL
Personalis
-$0.31-$0.26+$0.05-$0.26$17.12 million$17.35 million
2/10/2026Q1 2026
Quipt Home Medical Corp. stock logo
QIPT
Quipt Home Medical
-$0.10-$0.02+$0.08-$0.02$104.35 million$82.24 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
N/AN/AN/AN/AN/A
Charming Medical Ltd stock logo
MCTA
Charming Medical
N/AN/AN/AN/AN/A
Personalis, Inc. stock logo
PSNL
Personalis
N/AN/AN/AN/AN/A
Quipt Home Medical Corp. stock logo
QIPT
Quipt Home Medical
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
N/A
5.31
6.48
Charming Medical Ltd stock logo
MCTA
Charming Medical
N/AN/AN/A
Personalis, Inc. stock logo
PSNL
Personalis
N/A
6.76
6.61
Quipt Home Medical Corp. stock logo
QIPT
Quipt Home Medical
0.81
1.04
0.68

Institutional Ownership

CompanyInstitutional Ownership
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
48.06%
Charming Medical Ltd stock logo
MCTA
Charming Medical
N/A
Personalis, Inc. stock logo
PSNL
Personalis
61.91%
Quipt Home Medical Corp. stock logo
QIPT
Quipt Home Medical
42.85%

Insider Ownership

CompanyInsider Ownership
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
36.18%
Charming Medical Ltd stock logo
MCTA
Charming Medical
N/A
Personalis, Inc. stock logo
PSNL
Personalis
4.20%
Quipt Home Medical Corp. stock logo
QIPT
Quipt Home Medical
13.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
1,31529.75 million18.99 millionOptionable
Charming Medical Ltd stock logo
MCTA
Charming Medical
4916.94 millionN/AN/A
Personalis, Inc. stock logo
PSNL
Personalis
400104.68 million100.28 millionOptionable
Quipt Home Medical Corp. stock logo
QIPT
Quipt Home Medical
1,60044.47 million38.51 millionOptionable

Recent News About These Companies

The Quipt deal is good for shareholders, Leede says
Lakeview Investment Group urges Quipt to engage with bidder
Nuveen Takes Stake in Quipt Home Medical Corp. (QIPT)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Fulgent Genetics stock logo

Fulgent Genetics NASDAQ:FLGT

$14.90 -0.22 (-1.46%)
Closing price 05/5/2026 04:00 PM Eastern
Extended Trading
$14.74 -0.17 (-1.11%)
As of 05/5/2026 05:19 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.

Charming Medical stock logo

Charming Medical NASDAQ:MCTA

$29.36 +1.86 (+6.76%)
As of 05/5/2026 03:30 PM Eastern

We are a Hong Kong-based provider of Traditional Chinese Medicine (TCM)-inspired therapies and products. We offer a wide range of beauty, wellness, and postpartum services and products rooted and influenced by the principles and practices of TCM, such as the use of herbal ingredients, acupuncture techniques, Tuina massage, and dietary guidance. Operating under the Beauty Lab Group (“Beauty Lab”) brand, our Operating Subsidiaries in Hong Kong offer a wide range of TCM-inspired beauty, wellness, and postpartum therapies and products through our four wellness centers in Hong Kong. Our services are designed to meet diverse health improvement needs, including alleviating premenstrual syndrome, menstrual irregularities, dysmenorrhea, leukorrhea, pelvic inflammatory disease, menopausal care, breast health, and other common women’s health conditions. We believe that our TCM-inspired herbal therapies can help balance the female endocrine system and improve women’s constitution and overall health. Additionally, the Operating Subsidiaries offer TCM-inspired therapies tailored to men. We offer a wide range of beauty, wellness, and postpartum services for women with a focus on utilizing TCM approaches in addressing women’s health issues. Our beauty, wellness, and postpartum services include but are not limited to womb-warming therapy, BTS (Beauty, Tailor-made, Slim) pelvic detox therapy, agarwood moxibustion therapy, TCM-inspired prenatal massage, and Indonesian traditional abdominal binding. In addition, under the “Beauty Lab” brand, we also offer supplements products, including (i) TCM-inspired supplements products, such as Beauty Lab home herbal uterine care patch, probiotic intimate wash, and Yin nourishing pill sets, designed to support uterine health, improve physical weakness, and balance endocrine functions for female customers; and (ii) beauty products, including ginseng soothing anti-allergy moisturizing wash, which provide comprehensive care for skin issues, and scalp health. Moreover, we also offer consultancy services to provide TCM-inspired therapy technical training and dietary therapy training to other well-established and reputable beauty salons, massage centers, and similar institutions. In March 2025, we launched a franchise model for our Beauty Lab brand, granting exclusive rights to independent third parties (the “Franchisees”) to operate branded beauty and wellness outlets. Franchisees are authorized to offer services such as scalp and hair care and women’s wellness services under the Beauty Lab brand. We derive franchise-related revenue mainly from initial franchise fees, royalty and promotional fees, brand management fees, training and administration fees. As of March 31, 2025 and as of the date of this prospectus, we had 1 and 3 franchisees, respectively. We generated revenue of $6,221,751 and $6,015,375, respectively, and achieved a net income of $1,199,085 and $821,743, respectively, for the years ended March 31, 2025 and 2024. We generated revenue primarily through the following: (i) beauty, wellness, and postpartum services; (ii) sales of products; (iii) consultancy services; and (iv) franchise activities. For the fiscal years ended March 31, 2025 and 2024, the revenue from beauty, wellness, and postpartum services amounted to $5,967,277 and $5,813,814, representing 96.0% and 96.6% of total revenue, respectively. The revenue from sales of products was $207,766 and $88,992 for the fiscal years ended March 31, 2025 and 2024, representing 3.2% and 1.5% of total revenue, respectively. The revenue from consultancy services was nil and $112,569 for the fiscal years ended March 31, 2025 and 2024, representing 0% and 1.9% of total revenue, respectively. The revenue from franchise activities was $46,708 and nil for the fiscal years ended March 31, 2025 and 2024, representing 0.8% and 0% of total revenue, respectively. Our principal executive office is located Hong Kong.

Personalis stock logo

Personalis NASDAQ:PSNL

$5.56 -0.34 (-5.76%)
Closing price 05/5/2026 04:00 PM Eastern
Extended Trading
$5.56 +0.00 (+0.07%)
As of 05/5/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Personalis, Inc. develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer; and ImmunoID NeXT, a tissue-based test that combines whole exome (DNA) and whole transcriptome (RNA) sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for detection of MRD and recurrence in cancer; and NeXT Dx, a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. In addition, the company performs whole exome sequencing (WES) of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing (WGS) on human samples for research projects, such as population sequencing initiatives, as well as offers sequencing and data analysis services to support population sequencing initiatives. Its customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. The company was incorporated in 2011 and is headquartered in Fremont, California.

Quipt Home Medical stock logo

Quipt Home Medical NASDAQ:QIPT

Quipt Home Medical Corp., through its subsidiaries, engages in the provision of durable and home medical equipment and supplies in the United States. The company offers nebulizers, oxygen concentrators, and CPAP and BiPAP units; traditional and non-traditional durable medical respiratory equipment and services; non-invasive ventilation equipment, supplies, and services; and engages in the rental of medical equipment. It offers management of various chronic disease states focusing on patients with heart and pulmonary disease, sleep apnea, reduced mobility, and other chronic health conditions. The company was formerly known as Protech Home Medical Corp. and changed its name to Quipt Home Medical Corp. in May 2021. Quipt Home Medical Corp. is headquartered in Wilder, Kentucky.